The Latest Breaking News from Lars Fruergaard Jørgensen

The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis.

Novo Nordisk is investing $30 billion to expand production, but middlemen are pocketing 74 cents of every dollar it makes in sales.

Weight-loss drug Wegovy faces high demand, limited supply, and tricky health care systems to navigate.

Drug firm Novo Nordisk proposed singling out those most likely to return to work with its weight-loss injection

Germany exports Ozempic to the EU and the U.S., Karl Broich, president of the German Federal Institute for Drugs and Medical Devices, told Der Spiegel.

Novo Nordisk's CEO doesn't like proposed new EU rules that would cut the period for which drugmakers enjoy exclusivity for their products from 10 years to eight years.

Prominent pharma player Novo Nordisk (NVO) posted solid revenue and earnings growth in fiscal 2022. The company’s long-term growth is expected to be spearheaded by its immensely popular GLP-1 drug Wegovy. Given the potential of its current portfolio of drugs and drugs under research, investing in this stock could be…